210 related articles for article (PubMed ID: 32322605)
1. Successful Preclinical Development of Gene Therapy for Recombinase-Activating Gene-1-Deficient SCID.
Garcia-Perez L; van Eggermond M; van Roon L; Vloemans SA; Cordes M; Schambach A; Rothe M; Berghuis D; Lagresle-Peyrou C; Cavazzana M; Zhang F; Thrasher AJ; Salvatori D; Meij P; Villa A; Van Dongen JJM; Zwaginga JJ; van der Burg M; Gaspar HB; Lankester A; Staal FJT; Pike-Overzet K
Mol Ther Methods Clin Dev; 2020 Jun; 17():666-682. PubMed ID: 32322605
[TBL] [Abstract][Full Text] [Related]
2. Recombination-activating gene 1 (Rag1)-deficient mice with severe combined immunodeficiency treated with lentiviral gene therapy demonstrate autoimmune Omenn-like syndrome.
van Til NP; Sarwari R; Visser TP; Hauer J; Lagresle-Peyrou C; van der Velden G; Malshetty V; Cortes P; Jollet A; Danos O; Cassani B; Zhang F; Thrasher AJ; Fontana E; Poliani PL; Cavazzana M; Verstegen MM; Villa A; Wagemaker G
J Allergy Clin Immunol; 2014 Apr; 133(4):1116-23. PubMed ID: 24332219
[TBL] [Abstract][Full Text] [Related]
3. Correction of murine Rag1 deficiency by self-inactivating lentiviral vector-mediated gene transfer.
Pike-Overzet K; Rodijk M; Ng YY; Baert MR; Lagresle-Peyrou C; Schambach A; Zhang F; Hoeben RC; Hacein-Bey-Abina S; Lankester AC; Bredius RG; Driessen GJ; Thrasher AJ; Baum C; Cavazzana-Calvo M; van Dongen JJ; Staal FJ
Leukemia; 2011 Sep; 25(9):1471-83. PubMed ID: 21617701
[TBL] [Abstract][Full Text] [Related]
4. Partial correction of immunodeficiency by lentiviral vector gene therapy in mouse models carrying
Castiello MC; Di Verniere M; Draghici E; Fontana E; Penna S; Sereni L; Zecchillo A; Minuta D; Uva P; Zahn M; Gil-Farina I; Annoni A; Iaia S; Ott de Bruin LM; Notarangelo LD; Pike-Overzet K; Staal FJT; Villa A; Capo V
Front Immunol; 2023; 14():1268620. PubMed ID: 38022635
[TBL] [Abstract][Full Text] [Related]
5. Restoration of human B-cell differentiation into NOD-SCID mice engrafted with gene-corrected CD34+ cells isolated from Artemis or RAG1-deficient patients.
Lagresle-Peyrou C; Benjelloun F; Hue C; Andre-Schmutz I; Bonhomme D; Forveille M; Beldjord K; Hacein-Bey-Abina S; De Villartay JP; Charneau P; Durandy A; Fischer A; Cavazzana-Calvo M
Mol Ther; 2008 Feb; 16(2):396-403. PubMed ID: 18223550
[TBL] [Abstract][Full Text] [Related]
6. Correction of murine Rag2 severe combined immunodeficiency by lentiviral gene therapy using a codon-optimized RAG2 therapeutic transgene.
van Til NP; de Boer H; Mashamba N; Wabik A; Huston M; Visser TP; Fontana E; Poliani PL; Cassani B; Zhang F; Thrasher AJ; Villa A; Wagemaker G
Mol Ther; 2012 Oct; 20(10):1968-80. PubMed ID: 22692499
[TBL] [Abstract][Full Text] [Related]
7. Pretransplant mobilization with granulocyte colony-stimulating factor improves B-cell reconstitution by lentiviral vector gene therapy in SCID-X1 mice.
Huston MW; Riegman AR; Yadak R; van Helsdingen Y; de Boer H; van Til NP; Wagemaker G
Hum Gene Ther; 2014 Oct; 25(10):905-14. PubMed ID: 25222508
[TBL] [Abstract][Full Text] [Related]
8. A self-inactivating lentiviral vector for SCID-X1 gene therapy that does not activate LMO2 expression in human T cells.
Zhou S; Mody D; DeRavin SS; Hauer J; Lu T; Ma Z; Hacein-Bey Abina S; Gray JT; Greene MR; Cavazzana-Calvo M; Malech HL; Sorrentino BP
Blood; 2010 Aug; 116(6):900-8. PubMed ID: 20457870
[TBL] [Abstract][Full Text] [Related]
9. Transplantation of X-linked severe combined immunodeficient dogs with CD34+ bone marrow cells.
Hartnett BJ; Yao D; Suter SE; Ellinwood NM; Henthorn PS; Moore PE; McSweeney PA; Nash RA; Brown JD; Weinberg KI; Felsburg PJ
Biol Blood Marrow Transplant; 2002; 8(4):188-97. PubMed ID: 12014808
[TBL] [Abstract][Full Text] [Related]
10. Good Laboratory Practice Preclinical Safety Studies for GSK2696273 (MLV Vector-Based Ex Vivo Gene Therapy for Adenosine Deaminase Deficiency Severe Combined Immunodeficiency) in NSG Mice.
Carriglio N; Klapwijk J; Hernandez RJ; Vezzoli M; Chanut F; Lowe R; Draghici E; Nord M; Albertini P; Cristofori P; Richards J; Staton H; Appleby J; Aiuti A; Sauer AV
Hum Gene Ther Clin Dev; 2017 Mar; 28(1):17-27. PubMed ID: 28319446
[TBL] [Abstract][Full Text] [Related]
11. Long-Term Health Outcome and Quality of Life Post-HSCT for IL7Rα-, Artemis-, RAG1- and RAG2-Deficient Severe Combined Immunodeficiency: a Single Center Report.
Abd Hamid IJ; Slatter MA; McKendrick F; Pearce MS; Gennery AR
J Clin Immunol; 2018 Aug; 38(6):727-732. PubMed ID: 30105620
[TBL] [Abstract][Full Text] [Related]
12. Lentiviral Gene Therapy for Artemis-Deficient SCID.
Cowan MJ; Yu J; Facchino J; Fraser-Browne C; Sanford U; Kawahara M; Dara J; Long-Boyle J; Oh J; Chan W; Chag S; Broderick L; Chellapandian D; Decaluwe H; Golski C; Hu D; Kuo CY; Miller HK; Petrovic A; Currier R; Hilton JF; Punwani D; Dvorak CC; Malech HL; McIvor RS; Puck JM
N Engl J Med; 2022 Dec; 387(25):2344-2355. PubMed ID: 36546626
[TBL] [Abstract][Full Text] [Related]
13. Correction of murine SCID-X1 by lentiviral gene therapy using a codon-optimized IL2RG gene and minimal pretransplant conditioning.
Huston MW; van Til NP; Visser TP; Arshad S; Brugman MH; Cattoglio C; Nowrouzi A; Li Y; Schambach A; Schmidt M; Baum C; von Kalle C; Mavilio F; Zhang F; Blundell MP; Thrasher AJ; Verstegen MM; Wagemaker G
Mol Ther; 2011 Oct; 19(10):1867-77. PubMed ID: 21750532
[TBL] [Abstract][Full Text] [Related]
14. Lentiviral Gene Therapy Combined with Low-Dose Busulfan in Infants with SCID-X1.
Mamcarz E; Zhou S; Lockey T; Abdelsamed H; Cross SJ; Kang G; Ma Z; Condori J; Dowdy J; Triplett B; Li C; Maron G; Aldave Becerra JC; Church JA; Dokmeci E; Love JT; da Matta Ain AC; van der Watt H; Tang X; Janssen W; Ryu BY; De Ravin SS; Weiss MJ; Youngblood B; Long-Boyle JR; Gottschalk S; Meagher MM; Malech HL; Puck JM; Cowan MJ; Sorrentino BP
N Engl J Med; 2019 Apr; 380(16):1525-1534. PubMed ID: 30995372
[TBL] [Abstract][Full Text] [Related]
15. Recombinase Activating Gene 1 Deficiencies Without Omenn Syndrome May Also Present With Eosinophilia and Bone Marrow Fibrosis.
Ulusoy E; Karaca NE; Azarsiz E; Berdeli A; Aksu G; Kutukculer N
J Clin Med Res; 2016 May; 8(5):379-84. PubMed ID: 27081423
[TBL] [Abstract][Full Text] [Related]
16. Sustained transgene expression by human cord blood derived CD34+ cells transduced with simian immunodeficiency virus agmTYO1-based vectors carrying the human coagulation factor VIII gene in NOD/SCID mice.
Kikuchi J; Mimuro J; Ogata K; Tabata T; Ueda Y; Ishiwata A; Kimura K; Takano K; Madoiwa S; Mizukami H; Hanazono Y; Kume A; Hasegawa M; Ozawa K; Sakata Y
J Gene Med; 2004 Oct; 6(10):1049-60. PubMed ID: 15386735
[TBL] [Abstract][Full Text] [Related]
17. Clinical and Laboratory Factors Affecting the Prognosis of Severe Combined Immunodeficiency.
Ozturk E; Catak MC; Kiykim A; Baser D; Bilgic Eltan S; Yalcin K; Kasap N; Nain E; Bulutoglu A; Akgun G; Can Y; Sefer AP; Babayeva R; Caki-Kilic S; Tezcan Karasu G; Yesilipek A; Ozen A; Karakoc-Aydiner E; Baris S
J Clin Immunol; 2022 Jul; 42(5):1036-1050. PubMed ID: 35451701
[TBL] [Abstract][Full Text] [Related]
18. Preclinical Development of a Lentiviral Vector for Gene Therapy of X-Linked Severe Combined Immunodeficiency.
Poletti V; Charrier S; Corre G; Gjata B; Vignaud A; Zhang F; Rothe M; Schambach A; Gaspar HB; Thrasher AJ; Mavilio F
Mol Ther Methods Clin Dev; 2018 Jun; 9():257-269. PubMed ID: 29707600
[TBL] [Abstract][Full Text] [Related]
19. Evidence for engraftment of donor-type multipotent CD34+ cells in a patient with selective T-lymphocyte reconstitution after bone marrow transplantation for B-SCID.
Tjønnfjord GE; Steen R; Veiby OP; Friedrich W; Egeland T
Blood; 1994 Nov; 84(10):3584-9. PubMed ID: 7524743
[TBL] [Abstract][Full Text] [Related]
20. Characterization of rag1 mutant zebrafish leukocytes.
Petrie-Hanson L; Hohn C; Hanson L
BMC Immunol; 2009 Feb; 10():8. PubMed ID: 19192305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
